Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
The study team proposes a triple-blind, placebo-controlled, phase II clinical trial of
once-daily inhaled mometasone for 48 weeks (with 4-week washout at study completion) in
individuals with Sickle Cell Disease (SCD) who report episodic cough or wheeze (ECW) but do
not have asthma. Patients will be recruited from and followed in SCD clinics at participating
sites. The primary endpoint will be a reduction in sVCAM level of 20% or more in comparison
to placebo.